Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months

• HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)

• FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L

• BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)

Exclusion Criteria:

• Metformin contraindications according to local practice

• Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial